This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Integrated Whole-Genome Analysis of Hematologic Disorders

This study is currently recruiting participants.
See Contacts and Locations
Verified November 2016 by Stanford University
Information provided by (Responsible Party):
Stanford University Identifier:
First received: April 19, 2010
Last updated: November 8, 2016
Last verified: November 2016
We will use new technologies to look at the DNA, RNA, proteins, and metabolites in the disease-containing blood, bone marrow, or tissue and normal cells from the skin. Our goal is to analyze all of the genes in the diseased and normal skin sample. By comparing the results of the diseased sample and normal skin cells and the results of the two types of genetic information (DNA and RNA), we should be able to identify genetic changes that are important for the initiation, progression, or treatment response of that particular disorder.

Condition Intervention
Hematologic Diseases Procedure: Blood Draw Procedure: Skin Biopsy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • to identify mutations, changes in DNA copy number, structural rearrangements, or altered coding and non-coding RNA expression [ Time Frame: sample collection at time of routine visit ]

Biospecimen Retention:   Samples With DNA
blood, bone marrow, skin biopsy

Estimated Enrollment: 100
Study Start Date: September 2009
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
participants with hematologic disorders

Inclusion Criteria:

  1. 18 years of age or older
  2. Patient meets the clinical and/or pathologic criteria for the hematologic disorder being examined.
  3. Patient is willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.

Exclusion Criteria:

  1. Less than 18 years of age
  2. Patient is not willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01108159

Contact: Jason D Merker (650) 922-1885

United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Jason D Merker    650-922-1885   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Principal Investigator: James L Zehnder         
Sub-Investigator: Scott Boyd         
Sub-Investigator: Athena M. Cherry         
Sub-Investigator: Andrew Fire         
Sub-Investigator: Jason Robert Gotlib         
Sub-Investigator: Eleanor L. Marshall         
Sub-Investigator: Jason Merker         
Sub-Investigator: Stephen Tracy Oh         
Sponsors and Collaborators
Stanford University
Principal Investigator: James L Zehnder Stanford University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Stanford University Identifier: NCT01108159     History of Changes
Other Study ID Numbers: HEM0013
SU-09092009-3820 ( Other Identifier: Stanford University )
16329 ( Other Identifier: Stanford IRB )
Study First Received: April 19, 2010
Last Updated: November 8, 2016

Additional relevant MeSH terms:
Hematologic Diseases processed this record on September 21, 2017